%0 Journal Article
%T HER-2阳性乳腺癌的新辅助靶向药物应用现状
Application Status of Neoadjuvant Targeted Drugs for HER-2 Positive Breast Cancer
%A 王琪瑶
%A 熊斌
%A 冯其贞
%A 张亚杰
%J Journal of Clinical Personalized Medicine
%P 428-435
%@ 2334-3443
%D 2025
%I Hans Publishing
%R 10.12677/jcpm.2025.41064
%X 人表皮生长因子受体-2 (HER-2)阳性乳腺癌约占乳腺癌患者的20%~30%，同其他类型乳腺癌相比，其更易侵袭、复发时间更短、总体预后更差，且无瘤生存期及总生存期更短。乳腺癌新辅助化疗是指在手术治疗或放疗前进行化疗，以控制癌细胞扩散，抑制其增殖，使肿瘤降期和降级，目前在临床已得到广泛应用。随着针对HER-2基因过表达而研发的靶向药物出现，HER-2阳性乳腺癌患者的治疗得到了显著突破，尤其是此类药在新辅助治疗阶段的应用，已经被证实可以显著提高患者临床病理完全缓解(pCR)率，增加了患者的临床获益。随着研究的深入，越来越多新辅助阶段的药物被开发出来，这对改善患者预后具有积极的意义。本文就HER-2阳性乳腺癌患者新辅助阶段常用药物的应用作一综述。
HER-2 positive breast cancer accounts for about 20%~30% of breast cancer patients. Compared with other types of breast cancer, HER-2 positive breast cancer is more likely to invade, has shorter recurrence time, worse overall prognosis, and shorter disease-free survival and overall survival. Neoadjuvant chemotherapy for breast cancer refers to chemotherapy before surgical treatment or radiotherapy to control the spread of cancer cells, inhibit their proliferation, and downstage and downgrade tumors. It has been widely used in clinical practice. With the emergence of targeted drugs developed for HER-2 gene overexpression, the treatment of HER-2 positive breast cancer patients has made a significant breakthrough, especially the application of such drugs in the neoadjuvant treatment stage, which has been proved to significantly improve the patient’s pCR rate and increase the clinical benefits of patients. With the deepening of research, more and more new adjuvant drugs have been developed, which is of positive significance for improving the prognosis of patients. This article reviews the application of commonly used drugs in the neoadjuvant stage of HER-2 positive breast cancer patients.
%K 乳腺肿瘤，
%K HER-2阳性乳腺癌，
%K 靶向药物
Breast Cancer
%K HER-2 Positive Breast Cancer
%K Targeted Drug
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=107523